Portal de Periódicos da CAPES

Characteristics of male triple negative breast cancer: A population‐based study

2020; Wiley; Volume: 26; Issue: 9 Linguagem: Inglês

10.1111/tbj.14023

1524-4741

Sofia Ghani, Matthew Sochat, Jingqin Luo, Yu Tao, Foluso O. Ademuyiwa,

Breast Cancer Treatment Studies

The Breast JournalVolume 26, Issue 9 p. 1748-1755 ORIGINAL ARTICLE Characteristics of male triple negative breast cancer: A population-based study Sofia Ghani MD, Sofia Ghani MD Division of Hematology/Oncology, St. Louis University Hospital, St. Louis, Missouri, USASearch for more papers by this authorMatthew Sochat MD, Matthew Sochat MD Division of Hematology/Oncology, St. Louis University Hospital, St. Louis, Missouri, USASearch for more papers by this authorJingqin Luo PhD, Jingqin Luo PhD Division of Public Health Sciences, Alvin J. Siteman Cancer Center Biostatistics Core, Washington University School of Medicine, St. Louis, Missouri, USASearch for more papers by this authorYu Tao MD, Yu Tao MD Division of Public Health Sciences, Alvin J. Siteman Cancer Center Biostatistics Core, Washington University School of Medicine, St. Louis, Missouri, USASearch for more papers by this authorFoluso Ademuyiwa MD, Corresponding Author Foluso Ademuyiwa MD bisiademuyiwa@wustl.edu orcid.org/0000-0002-6766-2258 Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, Missouri, USA Correspondence Foluso Ademuyiwa, Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, 4921 Parkview Place, St. Louis, MO 63110. Email: bisiademuyiwa@wustl.eduSearch for more papers by this author Sofia Ghani MD, Sofia Ghani MD Division of Hematology/Oncology, St. Louis University Hospital, St. Louis, Missouri, USASearch for more papers by this authorMatthew Sochat MD, Matthew Sochat MD Division of Hematology/Oncology, St. Louis University Hospital, St. Louis, Missouri, USASearch for more papers by this authorJingqin Luo PhD, Jingqin Luo PhD Division of Public Health Sciences, Alvin J. Siteman Cancer Center Biostatistics Core, Washington University School of Medicine, St. Louis, Missouri, USASearch for more papers by this authorYu Tao MD, Yu Tao MD Division of Public Health Sciences, Alvin J. Siteman Cancer Center Biostatistics Core, Washington University School of Medicine, St. Louis, Missouri, USASearch for more papers by this authorFoluso Ademuyiwa MD, Corresponding Author Foluso Ademuyiwa MD bisiademuyiwa@wustl.edu orcid.org/0000-0002-6766-2258 Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, Missouri, USA Correspondence Foluso Ademuyiwa, Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, 4921 Parkview Place, St. Louis, MO 63110. Email: bisiademuyiwa@wustl.eduSearch for more papers by this author First published: 27 August 2020 https://doi.org/10.1111/tbj.14023Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Male triple negative breast cancer (TNBC), which lacks expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), is a very rare entity, comprising only a very small percentage of all male breast cancer cases. Management strategies are typically based off research conducted in female TNBC patients; however, there is still much that remains unknown in the male cohort, such as risk factors for developing these malignancies, the optimal treatment approach, and both short-term and long-term outcome data. In this retrospective cohort study, we aimed to address these concerns by assessing both the characteristics of male patients who develop TNBC as well as their outcomes. We harnessed data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program and identified 66 male patients diagnosed with TNBC between 2010 and 2016. Patients were stratified by several variables including age, insurance status, time period of diagnosis, histology, nodal status, tumor grade, tumor stage at diagnosis, and treatment strategy employed for the assessment of overall survival (OS) differences. Our analysis demonstrated that stage remains the most important prognostic factor for OS, with higher stage corresponding to worse OS. A significant OS benefit was also identified in men undergoing a total mastectomy, compared to partial mastectomy or no surgery at all. We also identified that male patients are more likely to present with more advanced disease stages compared to their female counterparts and, therefore, have worse outcomes on average. This may be due to various factors, including the rarity of male TNBC cases and less clear screening guidelines for male breast cancer in general. Trends toward poorer OS with higher tumor grade, higher tumor T stage, advanced age, earlier time period of diagnosis, and ductal histology were also identified, but did not achieve statistical significance. The remaining variables did not appear to influence outcomes in a meaningful manner. In summary, our study suggests, similar to population studies of women with TNBC, that tumor stage is a major prognostic factor of OS in men with TNBC. The data also suggest that the surgical treatment strategy employed is also likely of significance, with improved OS being seen with total mastectomies over partial mastectomies. Other variables such as tumor grade and T stage also likely play a role, but did not achieve statistical significance owing to the small population size. Owing to the rarity of cases, further studies of male TNBC are needed to better understand this rare entity and guide future management strategies. Citing Literature Volume26, Issue9September 2020Pages 1748-1755 RelatedInformation